<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7097833/results/search/test_trace/results.xml">
  <result pre="pandemic. Italy is the second most affected country by COVID-19" exact="infection" post="after China. The &quot;L. Spallanzani&quot; National Institute for the"/>
  <result pre="Currently, Italy is the second most affected country by COVID-19" exact="infection" post="after China. The first autochthonous infection case was confirmed"/>
  <result pre="affected country by COVID-19 infection after China. The first autochthonous" exact="infection" post="case was confirmed in Italy on February 21 2020"/>
  <result pre="definition Suspected case a. A person with an acute respiratory" exact="infection" post="(defined as acute onset of at least one of"/>
  <result pre="symptoms onset OR b. A person with an acute respiratory" exact="infection" post="and history of close contact with a probable or"/>
  <result pre="person with an acute respiratory infection and history of close" exact="contact" post="with a probable or confirmed COVID-19 case in the"/>
  <result pre="symptoms onset OR c. A person with a severe respiratory" exact="infection" post="(fever and at least one sign/symptom of respiratory disease"/>
  <result pre="has been observed, all patients with sings/symptoms of acute respiratory" exact="infection" post="should be considered as suspected cases. *According to WHO"/>
  <result pre="symptoms. Clinical management based on case severity Asymptomatic or mild" exact="infection" post="Cases not presenting any clinical feature suggesting a complicated"/>
  <result pre="goals of clinical management are: Application of strict measures of" exact="infection" post="prevention Clinical monitoring, in order to early identify possible"/>
  <result pre="signs of clinical worsening The application of strict measures of" exact="infection" post="prevention should be applied for all patients with suspected"/>
  <result pre="manifestations; stable clinical picture Minimal additional microbiologic diagnostics: Influenza virus" exact="detection" post="and/or respiratory agents multiplex PCR on single rhinopharyngeal swab"/>
  <result pre="clinical severity and/or respiratory impairment Additional microbiologic diagnostics: Influenza virus" exact="detection" post="and/or respiratory agents multiplex PCR on single rhinopharyngeal swab"/>
  <result pre="serology if available Urinary L. pneumophila and S. pneumoniae antigen" exact="detection" post="In case of availability of samples representative of lower"/>
  <result pre="score 3-4) Patients presenting severe respiratory conditions related to SARS-CoV-2" exact="infection" post="and/or to its complications. Adjunctive goals of clinical management"/>
  <result pre="drugs, aimed at rapidly reducing viral replication Empirical or targeted" exact="treatment" post="of possible bacterial co-infections; Prompt assessment of the need"/>
  <result pre="distress, consciousness disorders, hypotension, shock) Additional microbiologic diagnostics: Influenza virus" exact="detection" post="and/or respiratory agents multiplex PCR on single rhinopharyngeal swab"/>
  <result pre="serology if available Urinary L. pneumophila and S. pneumoniae antigen" exact="detection" post="In case of availability of sample representative of lower"/>
  <result pre="on the specific clinical picture (e.g. HIV test, P. jirovecii" exact="detection" post="on respiratory fluids, MRSA on nasal swab, etc…) Clinical"/>
  <result pre="immediate management of complications Active search for adjunctive or alternative" exact="diagnosis" post="Use of drugs aimed at reducing the impact of"/>
  <result pre="Multiorgan failure (MOF) Consciousness impairment Additional microbiologic diagnostics: Influenza virus" exact="detection" post="and/or respiratory agents multiplex PCR on single rhinopharyngeal swab"/>
  <result pre="serology if available Urinary L. pneumophila and S. pneumoniae antigen" exact="detection" post="In case of availability of samples representative of lower"/>
  <result pre="on the specific clinical picture (e.g. HIV test, P. jirovecii" exact="detection" post="on respiratory fluids, MRSA on nasal swab, etc…) Clinical"/>
  <result pre="old or new agents have been proposed and explored for" exact="treatment" post="of COVID-19 but clinical trials are still underway. Up"/>
  <result pre="for COVID-19 treatment. Dosage The recommended dosage for SARSCoV- 2" exact="infection" post="is chloroquine 500 mg bid or hydroxychloroquine 200 mg"/>
  <result pre="extrapyramidal symptoms It is important to check G6PDH before starting" exact="treatment" post="and during treatment to monitor complete blood count, QT"/>
  <result pre="is important to check G6PDH before starting treatment and during" exact="treatment" post="to monitor complete blood count, QT interval. Contraindicated in:"/>
  <result pre="which has been widely used for many years for the" exact="treatment" post="of HIV infection. Compared to remdesivir, lopinavir/ritonavir has the"/>
  <result pre="trial (RCTs) on lopinavir/ritonavir combined with IFNb use in MERS" exact="infection" post="is currently ongoing [MIRACLE Trial]. Mechanism of Action Lopinavir"/>
  <result pre="are available of the clinical efficacy of lopinavir/ritonavir in COVID-19" exact="infection" post="so far, it seems to rapidly reduce SARSCoV2 replication."/>
  <result pre="adverse reactions: gastrointestinal symptoms (nausea/vomiting, diarrhea) Monitoring transaminase levels during" exact="treatment" post="and drug-drug interactions before treatment start. In the light"/>
  <result pre="diarrhea) Monitoring transaminase levels during treatment and drug-drug interactions before" exact="treatment" post="start. In the light of the possible shortage of"/>
  <result pre="the U.S. Food and Drug Administration approved TCZ for the" exact="treatment" post="of cytokine release syndrome (CRS) consisting in a systemic"/>
  <result pre="the clinical and radiological outcome. Indications TCZ is a potential" exact="treatment" post="strategy in severe and critical COVID-19 patients. In particular,"/>
  <result pre="Dosage Although the optimal dose and schedule of TCZ for" exact="treatment" post="of CRS is not known, the intended posology is"/>
  <result pre="higher dose of TCZ. Thrombocytopenia and increase of liver function" exact="tests" post="have also been described. For more detailed information, the"/>
  <result pre="on March 13 2020. collab: WHO. Global Surveillance for human" exact="infection" post="with coronavirus disease (COVID-2019). Revised guidance, 27 February2020 Available"/>
  <result pre="medicine treatment. Biosci Trends 2020 Feb 9. doi: 10.5582/bst.2020.01030. LuHDrug" exact="treatment" post="options for the 2019- new coronavirus (2019-nCoV). Biosci Trends"/>
  <result pre="in Wuhan, China. Lancet2020;395:497-506.31986264 ChuCMChengVCHungIFet al.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findings. Thorax2004;59:252-6.14985565 MomattinHMohammedKZumlaAet"/>
  <result pre="Infect Dis2013;17:e792-8.23993766 MomattinHAl-AliAYAl-TawfiqJAA Systematic Review of therapeutic agents for the" exact="treatment" post="of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Travel"/>
  <result pre="Med2015;16:S23-40.26035358 VincentMJBergeronEBenjannetSet al.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. J Virol2005;2:69. YanYZouZSunYet al.Anti-malaria drug chloroquine is"/>
  <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal model. Cell Res2013;23:300-2.23208422 WangMCaoRZhangLet al.Remdesivir and"/>
  <result pre="Mar 9. GaoJTianZYangX.Breakthrough: Chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studies. Biosci Trends2020"/>
  <result pre="and Health Commission of Guangdong Province for chloroquine in the" exact="treatment" post="of novel coronavirus pneumonia. [Expert consensus on chloroquine phosphate"/>
  <result pre="novel coronavirus pneumonia. [Expert consensus on chloroquine phosphate for the" exact="treatment" post="of novel coronavirus pneumonia]. Zhonghua Jie He He Hu"/>
  <result pre="Zhi. 2020 Feb 20;43:E019.32075365 ChuCMChengVCHungIFet al.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findings. Thorax2004;59:252-6.14985565 ChanKSLaiSTChuCMet"/>
  <result pre="Common Marmoset. J Infect Dis2015;212:1904-13.26198719 HanWQuanBGuoYet al.The course of clinical" exact="diagnosis" post="and treatment of a case infected with coronavirus disease"/>
  <result pre="J Infect Dis2015;212:1904-13.26198719 HanWQuanBGuoYet al.The course of clinical diagnosis and" exact="treatment" post="of a case infected with coronavirus disease 2019. J"/>
  <result pre="COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the" exact="treatment" post="of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. J"/>
  <result pre="Nat Commun2020;11: 222.31924756 de WitEFeldmannFCroninJet al.Prophylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infection. Proc"/>
  <result pre="Access 10th March 2020) LeRQLiLYuanWet al.FDA approval summary: tocilizumab for" exact="treatment" post="of chimeric antigen receptor T cell induced severe or"/>
 </snippets>
</snippetsTree>
